ClinicalTrials.gg
CompletedNCT04678830Updated Apr 11, 2024Results posted

Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

A Phase 2 interventional study of Placebos and Leronlimab (700mg) in Coronavirus Disease 2019, sponsored by CytoDyn, Inc.. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-11.

Sponsored by CytoDyn, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
777th of 1,321
56 · median 91
Started
2021
with 503 others
Phase 2
349 of 1,859
14 open now
Registered
864th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 777th largest by enrollment of the 1,321 interventional ones that give a count, is one of 504 that started in 2021, is one of 349 in phase 2, and was the 864th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injections in subjects experiencing prolonged symptoms (> 12 weeks) of COVID-19.

Read the detailed description

This is a Phase 2, two-arm, randomized, double blind, placebo controlled multicenter study to evaluate the safety and efficacy of leronlimab (PRO 140) in patients with prolonged symptoms caused by Coronavirus Disease 2019 (COVID-19). Patients will be randomized to receive weekly doses of 700 mg leronlimab (PRO 140), or placebo. Leronlimab (PRO 140) and placebo will be administered via subcutaneous injection.

The study will have three phases: Screening Period, Treatment Period, and Follow-Up Period. Total study duration is 91 days. The study will be conducted at up to 5 centers in the United States and planned number of subjects are 50 subjects.

Visit schedule:

Visit 1 - Screening assessment Visit 2 - baseline, first dose Visit 3 - no dose, baseline+3 days Visit 4 - second dose, baseline + 7 days Visit 5 - no dose, safety assessment/con med, baseline +10 days Visit 6 - third dose, baselines + 14 days Visit 7 - no dose, safety assessments, baseline + 17 days Visit 8 - fourth dose, baseline +21 days Visit 9 - no dose, safety assessment, baseline + 24 days Visit 10 - fifth dose, baseline + 28 days Visit 11 - no dose, safety assessment, baseline + 31 days Visit 12 - sixth dose, baseline + 35 days Visit 13 - no dose, safety assessment, baseline + 38 days Visit 14 - seventh dose, baseline + 42 days Visit 15 - no dose, safety assessment, baseline + 45 days Visit 16 - eighth and final dose, baseline + 49 days Visit 17 - End of treatment, baseline + 56 days

03

Conditions studied

  • Coronavirus Disease 2019

Browse trials for

Keywords

  • COVID-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female adult ≥ 18 years of age at time of enrollment.
  2. Prior confirmed COVID-19 diagnosis by standard reverse transcriptase-polymerase chain reaction (RT-PCR) assay or equivalent testing
  3. Clinical Symptom Score of ≥6 AND at least two symptoms of moderate or higher severity as listed below at the time of Screening and currently experiencing two or more of the following symptoms consistent with COVID-19 infection for a prolonged period of time (>12 weeks).

    Clinical symptoms include the following:

    • Respiratory symptoms such as cough, sore throat, stuffy or runny nose, shortness of breath (difficulty breathing), tightness of chest.
    • Neurological symptoms such as difficulty in concentration (brain fog), sleep disturbance/insomnia, headache, dizziness, anxiety, tingling or numbness, loss of sense of smell or taste.
    • Cardiovascular and Gastrointestinal symptoms such as feeling of fast heartbeat, nausea, vomiting, diarrhea.
    • Musculoskeletal symptoms such as muscle aches/cramps, muscle weakness, joint pain/swelling.
    • General immune response symptoms such as fatigue (low energy or tiredness), chills or shivering, feeling hot or feverish, or exertional malaise (feeling of discomfort, illness, or lack of well-being after physical activity or mental stress).

    Note: Clinical Symptom Score is obtained from the patient diary (refer to Appendix 1 for scoring instructions).

  4. (ECG) with no findings as assessed by the Investigator.

    Note: Below are the examples of clinically significant and non-clinically significant ECG abnormalities:

    • ECG findings indicative of acute myocardial infarction or acute ischemic changes would be considered clinically significant abnormalities.
    • ECG finding such as atrial fibrillation, atrial flutter, paced rhythms in individuals who have undergone permanent pacemaker placement, evidence of prior infarction, unchanged stable conduction abnormalities e.g. right bundle branch block, or any other finding which does not significantly impact mortality would be considered non-clinically significant findings and subjects with these abnormal findings would be allowed to enroll in the study.
  5. Subject (or legally authorized representative) provides written prior to initiation of any study procedures.
  6. Men and women of and their partner must agree to use two medically accepted methods of (e.g., barrier contraceptives [male condom, female condom, or diaphragm with a spermicidal gel], hormonal contraceptives [implants, injectables, combination oral contraceptives, transdermal patches, or contraceptive rings], or one of the following methods of birth control (intrauterine devices, bilateral tubal occlusion, or vasectomy) or must practice complete sexual abstinence for the duration of the study (excluding women who are not of childbearing potential and men who have been sterilized).
  7. Females of child-bearing potential must have a negative urine pregnancy test at Screening Visit and prior to receiving the first dose of study drug; and Male participants must agree to use contraception and refrain from donating sperm for at least 90 days after the last dose of study intervention.
  8. Subject is willing and able to comply with scheduled visits, drug administration plan, laboratory tests, other study procedures and study restrictions

Exclusion criteria

Exclusion Criteria:

  1. Exhibiting signs of moderate or severe pulmonary disease (such as (COPD), asthma, or pulmonary fibrosis)
  2. Ongoing requirement of oxygen therapy
  3. Pulse oxygen saturation (SpO2) of \<94% on room air at the time of screening
  4. History of splenectomy
  5. Liver cirrhosis or patient showing signs of clinical jaundice at the time of screening
  6. Chronic kidney disease stage 4 or requiring dialysis at the time of screening
  7. (NYHA) Class III or IV congestive heart failure (CHF)
  8. Exhibiting signs of uncontrolled hypo-or hyper- thyroidism at the time of Screening
  9. Uncontrolled rheumatologic disorders at the time of screening
  10. History of organ transplantation or are candidates for organ transplantation at the time of screening
  11. History of Chronic Fatigue Syndrome prior to COVID-19 infection
  12. History of fibromyalgia prior to COVID-19 infection
  13. History of major psychiatric disorder including bipolar disorders, schizophrenia, schizoaffective disorder, major depression. Patients with major depression can be enrolled if patient has had no episode within the past year or is considered in remission or controlled by treatment.
  14. Any within the past 5 years, excluding successfully treated basal cell carcinoma or squamous cell carcinoma without evidence of .
  15. Any other serious systemic diseases which would interfere with study conduct or study results interpretation per the Investigator.
  16. Treatment with or immunomodulatory medications within 5 half-lives prior to screening. Patients on replacement therapy for adrenal insufficiency will be allowed. Patients on stable (> 3 months) low dose ≤ 5 mg Prednisone will be allowed.
  17. History of allergic reactions attributed to compounds of similar chemical or biologic composition to leronlimab (PRO 140) are not eligible
  18. Ongoing use of CCR5 antagonist
  19. Inability to provide or to comply with test requirements
  20. Consideration by the investigator, for safety reasons, that the subject is an unsuitable candidate to receive study treatment
  21. Pregnancy or breast feeding
  22. Participating in another study for an treatment
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Syringes containing normal saline for injection were prepared by an unblinded pharmacist at the clinical sites for use as the placebo.

    Drug: Placebos

  • Experimental
    700mg Leronlimab

    Each vial of active contains 350mg of leronlimab at a concentration of 175mg/ml (nominal 2mL fill volume) in formulation buffer containing histidine, glycine, sodium chloride, sorbitol, polysorbate 20 and sterile water for injections

    Drug: Leronlimab (700mg)

Interventions

  • DrugPlacebos

    Placebos

    Also known as: placebo

  • Leronlimab (PRO) 140 is a humanized IgG4, monoclonal antibody (mAb) to the C-C chemokine receptor type 5 (CCR5)

    Also known as: Pro140

06

What researchers measure

Primary outcomes

  1. Changes From Baseline in Daily COVID-19-related Symptom Severity Score Through Day 56.

    Changes in common COVID-19-related symptoms were evaluated daily by the patient using a patient diary between start and end of treatment. The diary is shown in Appendix 17.1 in the protocol and covers patient-reported changes for symptoms (ranked as none = 0, mild = 1, moderate = 2 or severe = 3) of cough, sore throat, stuffy or runny nose, difficulty breathing, feeling tightness in chest, feeling fast heartbeat, fatigue, exertional malaise, muscle aches and cramps, muscle weakness, joint pain and swelling, shivering and chills, feeling hot or feverish, difficulty concentrating, insomnia, headache, dizziness, anxiety, tingling or numbness, nausea, vomiting, diarrhea, sense of smell, sense of taste. Maximum score could be 70 (22 parameters with scores up to 3, two parameters with scores up to 2), lowest score could be 0. A negative value shows improvement in symptoms. The lower the value, the greater the improvement (i.e., a score of -16 is greater improvement than a score of -8).

    Time frame: Changes in COVID-19 related symptoms from baseline (start of treatment) and day 56 (end of treatment)

Secondary outcomes

  1. Duration of COVID-19 Associated Symptoms From Start of Study Treatment (Day 0) Based on Self-assessment Using Daily Symptom Diary.

    Number of days when any symptoms scored as moderate or severe at baseline (Day 0) are still scored as moderate or severe through day 56 (end of treatment) or symptoms scored as mild or absent at baseline are scored as mild or worse at day 56 (end of treatment).

    Time frame: Duration of symptoms from baseline (day 0, start of treatment) and day 56 (end of treatment)

  2. Number of Days Free of Symptoms Associated With COVID-19 That Were Present at the Start of Study Treatment (Day 0) Based on Self-assessment Using Daily Symptom Diary.

    Symptom-free days are defined as number of days when any symptoms scored as mild, moderate or severe at baseline are scored as absent (or none) through Day 56 (end of treatment) using a self-assessment diary.

    Time frame: Between start of treatment (day0) and day 56 (end of treatment)

  3. Progression (or Worsening) of COVID-19-associated Symptoms Through Day 56 Compared to Baseline.

    Progression or worsening of symptoms is defined as number of days when any symptoms scored as 2 at baseline scored as 3 through day 56 or 1 at baseline are scored as 2 or 3 through day 56 or scored 0 at study entry scored as 1, 2 or 3 through day 56. No change in symptoms would give a score of 0, symptom progression would give a positive number, symptom improvement would a negative number. Minimum baseline symptom score for eligibility for the study was 6. Maximum symptom score is 70, therefore if all symptoms progressed to the severest level the change in score would be +64. If all patients had a severe score for all symptoms at baseline and all improved to no symptoms at day 56, the maximum improvement in score would be -70.

    Time frame: Between start of treatment (day0) and day 56 (end of treatment)

  4. Change From Baseline in PROMIS® Fatigue Score at Days 7,14, 21, 28, 35, 42 and End of Treatment (Day 56).

    Change from baseline in physical and psychological fatigue measured using the PROMIS® scale. A decrease in the score compared to baseline shows an improvement in the symptom. PROMIS definition - Patient-Reported Outcomes Measurement Information System. The Fatigue Short Form (4a) was used (Section 17.3 Appendix 3 of protocol). Raw fatigue scores range from 4 to 20 and are converted to a T-score metric where the response from the general population is set at 50 with standard deviations at 10; a score of greater than 60 would be one std dev greater than the general population, meaning more fatigue. A link to the fatigue score maps is provided in the hyperlinks section. The minimum fatigue T-score is 33.7 (with a std error of 4.9) and a maximum score of 75.8 (with a std error of 3.9). The higher the score, the more fatigue. A decrease in the fatigue score from baseline to day 28 and day 56 would indicate decrease in fatigue.

    Time frame: Between Baseline (day 0), Visit 4 (day 7), Visit 6 (day 14), Visit 8 (day 21) Visit 10 (day 28), Visit 12 (day 35), Visit 14 (day 42), Visit 16 (Day 56) and Visit 17 (day 56, end of treatment).

  5. Change From Baseline in PROMIS® Cognitive Function Score at Days 7, 14, 21, 28, 35, 42, 49 and End of Treatment (d56)

    Change in cognitive function score between baseline, day 28 and day 56 were measured using the PROMIS Cognitive Function Assessment Short Form 4a. Higher scores on the PROMIS Cognitive Function Assessment indicate better perceived cognitive functioning. Answers to 4 questions with scores ranging from 1 (very often - several times a day) to 5 (never) provide raw scores that are then normalized T scores. A T score of 50 is the mean of the general population, with std devs of 10, therefore a score of 40 is one std dev lower than that of the general population. The lowest raw score (4) converts to a T score of 24.99 while the highest raw score (20) converts to a T score of 61.13. A link to the PROMIS scoring maps is provided in the hyperlinks section. An increase in score for cognitive function assessment represents an increase in cognitive function

    Time frame: Baseline (start of treatment), day 28 and day 56 (end of treatment)

  6. Change From Baseline in PROMIS® Sleep Disturbance Score at Days 7,14, 21, 28, 35, 42, 49 and End of Treatment (Day 56).

    Assessment of change in sleep disturbance between baseline, day 28 and day 56 used the PROMIS® Sleep Disturbance Short Form (see Appendix 5 in Section 17 of the protocol). Four questions are scored between 1 (best score for good quality sleep) and 5 (worst score) such that the lower the score, the better the sleep. Raw scores are converted to a T-score with a mean of 50 and a standard deviation (SD) of 10 for the general population. T-scores of 60 are one SD worse than average (worse quality sleep). By comparison, Sleep Disturbance T-scores of 40 are one SD better than average. The PROMIS Sleep Disturbance scoring manual shows the lowest sleep disturbance score of 4 converting to a T score of 32 with a std error of 5.2, while the highest score of 20 converts to a T score of 73.3 with a std error of 4.6. The change from baseline is based on patients with paired values.

    Time frame: Between Baseline (day 0), Visit 4 (day 7), Visit 6 (day 14), Visit 8 (day 21) Visit 10 (day 28), Visit 12 (day 35), Visit 14 (day 42), Visit 16 (Day 56) and Visit 17 (day 56, end of treatment).

  7. Number of Participants Requiring Hospitalization During the Treatment Phase

    Number of participants who required hospitalization during the treatment phase.

    Time frame: Between baseline (start of treatment) and day 56 (end of treatment)

  8. Duration (Days) of Hospitalization During the Treatment Phase

    Duration (in days) of hospitalization required during treatment phase

    Time frame: Between baseline (start of treatment) and day 56 (end of treatment)

Other outcomes

  1. Change From Baseline in Pulse Oxygen Saturation (SpO2) at Day 7, 14, 21, 28, 35, 42, 49, and 56

    Exploratory Outcome - Change from baseline in pulse oxygen saturation (SpO2) at Day 7, 14, 21, 28, 35, 42, 49, and 56

    Time frame: Change between baseline (start of treatment) and Day 7, 14, 21, 28, 35, 42, 49, and 56 (end of treatment).

  2. Change From Baseline in Serum Cytokine and Chemokine Levels on Days 28 and 56.

    Exploratory Outcome - Change from baseline in serum cytokine and chemokine levels

    Time frame: Change between baseline (start of treatment) and days 28 and 56 (end of treatment)

  3. Change From Baseline in CD4+ and CD8+ T Cell Count on Days 28 and 56.

    Exploratory Outcome - Change from baseline in CD4+ and CD8+ T cell count

    Time frame: Change between baseline (start of treatment) and days 28 and 56 (end of treatment)

  4. Change From Baseline in Transforming Growth Factor Beta 1 (TGF beta1) on Days 28 and 56

    Exploratory Outcome - change in TGF-b1 from baseline to days 28 and 56 (end of treatment)

    Time frame: Change between baseline (start of treatment) and days 28 and 56 (end of treatment)

  5. Change From Baseline in C-reactive Protein (CRP) on Days 28 and 56

    Exploratory Outcome - Change in C-reactive Protein (CRP) from baseline to Days 28 and 56 (end of treatment)

    Time frame: Change between baseline (start of treatment) and days 28 and 56 (end of treatment)

  6. Change From Baseline in CCR5 Receptor Occupancy on Days 28 and 56.

    Exploratory Outcome - Change in CCR5 receptor occupancy from baseline and days 28 and 56 (end of treatment)

    Time frame: Change between baseline (start of treatment) and days 28 and 56 (end of treatment)

  7. Exploration of Biomarkers That May Predict and/or Act as Pharmacodynamic Indicators of Pharmacologic Activity of Leronlimab.

    Exploratory Outcome - Exploration of biomarkers that may predict and/or act as pharmacodynamic indicators of pharmacologic activity of leronlimab.

    Time frame: 91 Days

  8. Incidence of Treatment-related Adverse Events (TEAEs)

    Safety Measurement - incidence of treatment emergent adverse events

    Time frame: Between baseline and day 91

  9. Incidence and Severity of Treatment-emergent Adverse Events (TEAEs)

    Safety Measures - Incidence and severity of treatment-emergent adverse events

    Time frame: Between baseline and day 91

  10. Incidence of Serious Adverse Events (SAEs)

    Safety Measures - incidence of severe adverse events

    Time frame: Between baseline and day 91

  11. Incidence of TEAEs and SAEs Leading to Discontinuation of Study Medication.

    Safety Measures - incidence of TEAEs and SAEs leading to discontinuation of study medication

    Time frame: Between baseline and day 56

  12. Changes in Blood Chemistry, Hematology and Coagulation Parameter Results

    Safety Measures - Changes in blood chemistry, hematology and coagulation parameter results

    Time frame: Between baseline and day 91

  13. Changes in Vital Signs Including Temperature, Pulse, Respiratory Rate, Systolic and Diastolic Blood Pressure

    Safety Measures - Changes in vital signs including temperature, pulse, respiratory rate, systolic and diastolic blood pressure

    Time frame: Between baseline and day 91

  14. Changes in Physical Examination Results

    Safety Measures - Changes in physical examination results

    Time frame: Between baseline and day 91

  15. Changes in Electrocardiogram (ECG) Results

    Safety Measures - changes in electrocardiogram results

    Time frame: Change between baseline and day 91

07

Results

Posted Apr 11, 2024

Participant flow

Fifty six (56) subjects were enrolled in the study with 28 subjects in each treatment arm. All patients were enrolled under protocol version 3.0 (effective date 25-Feb-2021). The study was performed between 01 March 2021 and 01 July 2021.

Participant flow — Overall Study
MilestonePlacebo700mg Leronlimab
Started2828
Completed2627
Not completed21
Withdrew: Lack of efficacy20
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryChanges From Baseline in Daily COVID-19-related Symptom Severity Score Through Day 56.

Changes in common COVID-19-related symptoms were evaluated daily by the patient using a patient diary between start and end of treatment. The diary is shown in Appendix 17.1 in the protocol and covers patient-reported changes for symptoms (ranked as none = 0, mild = 1, moderate = 2 or severe = 3) of cough, sore throat, stuffy or runny nose, difficulty breathing, feeling tightness in chest, feeling fast heartbeat, fatigue, exertional malaise, muscle aches and cramps, muscle weakness, joint pain and swelling, shivering and chills, feeling hot or feverish, difficulty concentrating, insomnia, headache, dizziness, anxiety, tingling or numbness, nausea, vomiting, diarrhea, sense of smell, sense of taste. Maximum score could be 70 (22 parameters with scores up to 3, two parameters with scores up to 2), lowest score could be 0. A negative value shows improvement in symptoms. The lower the value, the greater the improvement (i.e., a score of -16 is greater improvement than a score of -8).

Time frame:
Changes in COVID-19 related symptoms from baseline (start of treatment) and day 56 (end of treatment)
Reported as:
Mean · units on a scale
Changes From Baseline in Daily COVID-19-related Symptom Severity Score Through Day 56.
units on a scale700mg LeronlimabPlacebo
Changes From Baseline in Daily COVID-19-related Symptom Severity Score Through Day 56.-16.3 ± 13.14-8.1 ± 12.27
SecondaryDuration of COVID-19 Associated Symptoms From Start of Study Treatment (Day 0) Based on Self-assessment Using Daily Symptom Diary.

Number of days when any symptoms scored as moderate or severe at baseline (Day 0) are still scored as moderate or severe through day 56 (end of treatment) or symptoms scored as mild or absent at baseline are scored as mild or worse at day 56 (end of treatment).

Time frame:
Duration of symptoms from baseline (day 0, start of treatment) and day 56 (end of treatment)
Reported as:
Mean · days
Duration of COVID-19 Associated Symptoms From Start of Study Treatment (Day 0) Based on Self-assessment Using Daily Symptom Diary.
days700mg LeronlimabPlacebo
Duration (days) of cough14.9 ± 18.87.8 ± 12.8
Duration (days) of sore throat10.6 ± 15.79.4 ± 13.4
Duration (days) of Stuff/Runny Nose19.3 ± 23.020.7 ± 20.9
Duration (days) of shortness of breath11.5 ± 17.413.9 ± 17.4
Duration (days) of tightness of chest10.3 ± 14.812.3 ± 17.1
Duration (days) of fast heartbeat14.8 ± 18.716.0 ± 15.6
Duration (days) of fatigue6.5 ± 14.010.6 ± 18.4
Duration (days) of exertional malaise12.7 ± 18.810.6 ± 15.3
Duration (days) muscle aches / cramps16.5 ± 19.617.7 ± 16.6
Duration (days) of Muscle Weakness17.1 ± 19.420.8 ± 17.9
Duration (days) joint pain/swelling15.9 ± 16.718.3 ± 18.6
Duration (days) of chills or shivering6.6 ± 11.13.9 ± 7.7
Duration (days) of feeling hot or feverish10.5 ± 13.69.9 ± 16.2
Duration (days) of difficulty in concentration15.6 ± 20.311.8 ± 17.7
Duration (days) of sleep disturbance13.3 ± 17.214.4 ± 17.5
Duration (days) of headache16.0 ± 16.617.8 ± 18.0
Duration (days) of dizziness11.8 ± 17.616.9 ± 18.6
Duration (days) of anxiety16.8 ± 22.315.1 ± 17.4
Duration (days) of tingling or numbness14.0 ± 19.318.3 ± 19.4
Duration (days) of nausea6.8 ± 9.88.5 ± 12.5
Duration (days) of vomiting0.3 ± 0.70.6 ± 1.6
Duration (days) of diarrhea8.5 ± 13.77.1 ± 9.5
Duration (days) of change to sense of smell16.8 ± 21.28.5 ± 15.5
Duration (days) in change of sense of taste13.5 ± 18.38.6 ± 17.0
SecondaryNumber of Days Free of Symptoms Associated With COVID-19 That Were Present at the Start of Study Treatment (Day 0) Based on Self-assessment Using Daily Symptom Diary.

Symptom-free days are defined as number of days when any symptoms scored as mild, moderate or severe at baseline are scored as absent (or none) through Day 56 (end of treatment) using a self-assessment diary.

Time frame:
Between start of treatment (day0) and day 56 (end of treatment)
Reported as:
Mean · Days
Number of Days Free of Symptoms Associated With COVID-19 That Were Present at the Start of Study Treatment (Day 0) Based on Self-assessment Using Daily Symptom Diary.
Days700mg LeronlimabPlacebo
Days free of cough16.8 ± 19.411.3 ± 17.1
Days free of sore throat4.9 ± 9.811.5 ± 18.5
Days free of stuffy or runny nose8.7 ± 13.212.8 ± 17.7
Days free of shortness of breath8.2 ± 12.015.0 ± 17.0
Days free of tightness of chest10.3 ± 16.113.4 ± 19.0
Days free of fast heartbeat12.8 ± 16.516.4 ± 18.8
Days free of fatigue3.9 ± 7.55.4 ± 10.9
Days free of exertional malaise7.2 ± 10.511.1 ± 15.0
Days free of muscle aches and cramps9.1 ± 13.714.2 ± 15.5
Days free of muscle weakness9.5 ± 14.712.0 ± 16.1
Days free of joint pain/swelling10.5 ± 17.85.1 ± 12.7
Days free of chills or shivering12.6 ± 19.416.6 ± 21.6
Days free of being hot or feverish14.8 ± 20.414.5 ± 18.2
Days free from difficulty concentrating4.6 ± 9.17.4 ± 13.3
Days free from sleep disturbance10.3 ± 12.113.6 ± 15.7
Days free from headache15.4 ± 16.212.5 ± 16.4
Days free from dizziness11.0 ± 18.59.9 ± 15.3
Days free from anxiety5.1 ± 11.012.4 ± 16.4
Days free from tingling or numbness16.5 ± 20.19.0 ± 15.8
Days free from nausea14.0 ± 19.813.9 ± 18.1
Days free from diarrhea8.3 ± 15.013.6 ± 18.3
Days free from change in sense of smell7.8 ± 14.26.9 ± 15.3
Days free from change in sense of taste8.8 ± 16.38.0 ± 16.9
SecondaryProgression (or Worsening) of COVID-19-associated Symptoms Through Day 56 Compared to Baseline.

Progression or worsening of symptoms is defined as number of days when any symptoms scored as 2 at baseline scored as 3 through day 56 or 1 at baseline are scored as 2 or 3 through day 56 or scored 0 at study entry scored as 1, 2 or 3 through day 56. No change in symptoms would give a score of 0, symptom progression would give a positive number, symptom improvement would a negative number. Minimum baseline symptom score for eligibility for the study was 6. Maximum symptom score is 70, therefore if all symptoms progressed to the severest level the change in score would be +64. If all patients had a severe score for all symptoms at baseline and all improved to no symptoms at day 56, the maximum improvement in score would be -70.

Time frame:
Between start of treatment (day0) and day 56 (end of treatment)
Reported as:
Mean · score on a scale
Progression (or Worsening) of COVID-19-associated Symptoms Through Day 56 Compared to Baseline.
score on a scale700mg LeronlimabPlacebo
Cough-0.6 ± 0.8-0.4 ± 0.9
Sore throat-0.1 ± 0.7-0.2 ± 0.8
Stuffy or runny nose-0.7 ± 0.8-0.1 ± 0.8
Shortness of breath-0.8 ± 1.0-0.6 ± 0.9
Tightness of chest-0.6 ± 0.9-0.3 ± 0.9
Fast heartbeat-0.8 ± 0.8-0.5 ± 1.0
Fatigue-1.1 ± 0.9-1.1 ± 1.0
Exertional Malaise-1.1 ± 1.1-0.9 ± 1.0
Muscle aches and cramps-0.9 ± 0.9-0.7 ± 0.9
Muscle weakness-0.9 ± 1.1-0.5 ± 0.8
Joint Pain/swelling-0.8 ± 0.7-0.3 ± 0.9
Chills and shivering-0.6 ± 0.6-0.5 ± 0.8
Hot or feverish-0.5 ± 0.8-0.6 ± 1.1
Difficulty in concentrating-1.0 ± 1.0-1.1 ± 1.0
Sleep disturbance-1.2 ± 0.9-1.1 ± 1.0
Headache-1.0 ± 1.0-0.7 ± 1.0
Dizziness-0.7 ± 1.0-0.4 ± 0.9
Anxiety-0.7 ± 0.9-0.8 ± 0.8
Tingling or numbness-0.8 ± 1.0-0.3 ± 0.9
Nausea-0.6 ± 0.9-0.5 ± 0.9
Vomiting0.0 ± 0.10.0 ± 0.1
Diarrhea-0.0 ± 0.6-0.6 ± 1.0
Sense of Smell-0.3 ± 0.5-0.2 ± 0.4
Sense of taste-0.3 ± 0.5-0.2 ± 0.4
SecondaryChange From Baseline in PROMIS® Fatigue Score at Days 7,14, 21, 28, 35, 42 and End of Treatment (Day 56).

Change from baseline in physical and psychological fatigue measured using the PROMIS® scale. A decrease in the score compared to baseline shows an improvement in the symptom. PROMIS definition - Patient-Reported Outcomes Measurement Information System. The Fatigue Short Form (4a) was used (Section 17.3 Appendix 3 of protocol). Raw fatigue scores range from 4 to 20 and are converted to a T-score metric where the response from the general population is set at 50 with standard deviations at 10; a score of greater than 60 would be one std dev greater than the general population, meaning more fatigue. A link to the fatigue score maps is provided in the hyperlinks section. The minimum fatigue T-score is 33.7 (with a std error of 4.9) and a maximum score of 75.8 (with a std error of 3.9). The higher the score, the more fatigue. A decrease in the fatigue score from baseline to day 28 and day 56 would indicate decrease in fatigue.

Time frame:
Between Baseline (day 0), Visit 4 (day 7), Visit 6 (day 14), Visit 8 (day 21) Visit 10 (day 28), Visit 12 (day 35), Visit 14 (day 42), Visit 16 (Day 56) and Visit 17 (day 56, end of treatment).
Reported as:
Mean · Units on a scale
Change From Baseline in PROMIS® Fatigue Score at Days 7,14, 21, 28, 35, 42 and End of Treatment (Day 56).
Units on a scale700mg LeronlimabPlacebo
Baseline score (day 0)68.4 ± 6.566.6 ± 7.1
Change from baseline to visit 4 (day 7)-5.3 ± 9.9-6.1 ± 8.5
Change from baseline to visit 6 (day 14)-7.6 ± 10.7-7.6 ± 8.5
Change from baseline to visit 8 (day 21)-8.4 ± 14.6-10.2 ± 10.1
Change from baseline to visit 10 (day 28)-8.8 ± 12.1-7.5 ± 10.5
Change from baseline to Visit 12 (day 25)-11.1 ± 13.4-8.6 ± 10.8
Change from baseline to visit 14 (day 42)-11.0 ± 14.0-8.1 ± 11.2
change from baseline to visit 16 (day 49)-11.8 ± 12.9-11.0 ± 11.5
Change from baseline to end of treatment (day 56)-11.1 ± 11.9-10.2 ± 10.8
SecondaryChange From Baseline in PROMIS® Cognitive Function Score at Days 7, 14, 21, 28, 35, 42, 49 and End of Treatment (d56)

Change in cognitive function score between baseline, day 28 and day 56 were measured using the PROMIS Cognitive Function Assessment Short Form 4a. Higher scores on the PROMIS Cognitive Function Assessment indicate better perceived cognitive functioning. Answers to 4 questions with scores ranging from 1 (very often - several times a day) to 5 (never) provide raw scores that are then normalized T scores. A T score of 50 is the mean of the general population, with std devs of 10, therefore a score of 40 is one std dev lower than that of the general population. The lowest raw score (4) converts to a T score of 24.99 while the highest raw score (20) converts to a T score of 61.13. A link to the PROMIS scoring maps is provided in the hyperlinks section. An increase in score for cognitive function assessment represents an increase in cognitive function

Time frame:
Baseline (start of treatment), day 28 and day 56 (end of treatment)
Reported as:
Mean · units on a scale
Change From Baseline in PROMIS® Cognitive Function Score at Days 7, 14, 21, 28, 35, 42, 49 and End of Treatment (d56)
units on a scale700mg LeronlimabPlacebo
Baseline (day 0)29.6 ± 5.534.6 ± 9.5
Change from baseline to visit 4 (day 7)5.1 ± 8.92.7 ± 8.2
Change from baseline to visit 6 (day 14)7.4 ± 9.64.9 ± 9.5
Change from baseline to visit 8 (day 21)7.4 ± 10.04.6 ± 7.9
Change from baseline to visit 10 (day 28)9.0 ± 8.94.1 ± 8.0
Change from baseline to visit 12 (day 35)10.1 ± 9.46.2 ± 9.1
Change from baseline to visit 14 (day 42)10.8 ± 11.26.2 ± 8.6
Change from baseline to visit 16 (day 49)10.3 ± 10.87.4 ± 9.7
Change from baseline to end of treatment (day 56)10.9 ± 10.86.3 ± 8.8
SecondaryChange From Baseline in PROMIS® Sleep Disturbance Score at Days 7,14, 21, 28, 35, 42, 49 and End of Treatment (Day 56).

Assessment of change in sleep disturbance between baseline, day 28 and day 56 used the PROMIS® Sleep Disturbance Short Form (see Appendix 5 in Section 17 of the protocol). Four questions are scored between 1 (best score for good quality sleep) and 5 (worst score) such that the lower the score, the better the sleep. Raw scores are converted to a T-score with a mean of 50 and a standard deviation (SD) of 10 for the general population. T-scores of 60 are one SD worse than average (worse quality sleep). By comparison, Sleep Disturbance T-scores of 40 are one SD better than average. The PROMIS Sleep Disturbance scoring manual shows the lowest sleep disturbance score of 4 converting to a T score of 32 with a std error of 5.2, while the highest score of 20 converts to a T score of 73.3 with a std error of 4.6. The change from baseline is based on patients with paired values.

Time frame:
Between Baseline (day 0), Visit 4 (day 7), Visit 6 (day 14), Visit 8 (day 21) Visit 10 (day 28), Visit 12 (day 35), Visit 14 (day 42), Visit 16 (Day 56) and Visit 17 (day 56, end of treatment).
Reported as:
Mean · score on a scale
Change From Baseline in PROMIS® Sleep Disturbance Score at Days 7,14, 21, 28, 35, 42, 49 and End of Treatment (Day 56).
score on a scale700mg LeronlimabPlacebo
Baseline score (day 0)60.2 ± 8.058.3 ± 8.5
Change from baseline to visit 4 (day 7)-4.1 ± 8.6-1.9 ± 6.2
Change from baseline to visit 6 (day 14)-5.3 ± 9.6-3.4 ± 8.0
Change from baseline visit 8 (day 21)-7.7 ± 10.2-5.1 ± 7.1
Change from baseline to visit 10 (day 28)-7.2 ± 8.9-5.7 ± 9.2
Change from baseline to visit 12 (day 35)-8.3 ± 10.8-4.2 ± 6.5
Change from baseline to visit 14 (day 42)-7.7 ± 10.7-5.3 ± 7.9
Change from baseline to visit 16 (day 49)-7.6 ± 9.5-6.0 ± 10.4
Change from baseline to end of treatment (day 56)-8.3 ± 9.4-5.5 ± 9.4
SecondaryNumber of Participants Requiring Hospitalization During the Treatment Phase

Number of participants who required hospitalization during the treatment phase.

Time frame:
Between baseline (start of treatment) and day 56 (end of treatment)
Reported as:
Count of participants · Participants
Number of Participants Requiring Hospitalization During the Treatment Phase
Participants700mg LeronlimabPlacebo
Number of Participants Requiring Hospitalization During the Treatment Phase00
SecondaryDuration (Days) of Hospitalization During the Treatment Phase

Duration (in days) of hospitalization required during treatment phase

Time frame:
Between baseline (start of treatment) and day 56 (end of treatment)
Reported as:
Number · days
Duration (Days) of Hospitalization During the Treatment Phase
days700mg LeronlimabPlacebo
Duration (Days) of Hospitalization During the Treatment Phase00
Other pre-specifiedChange From Baseline in Pulse Oxygen Saturation (SpO2) at Day 7, 14, 21, 28, 35, 42, 49, and 56

Exploratory Outcome - Change from baseline in pulse oxygen saturation (SpO2) at Day 7, 14, 21, 28, 35, 42, 49, and 56

Time frame:
Change between baseline (start of treatment) and Day 7, 14, 21, 28, 35, 42, 49, and 56 (end of treatment).

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in Serum Cytokine and Chemokine Levels on Days 28 and 56.

Exploratory Outcome - Change from baseline in serum cytokine and chemokine levels

Time frame:
Change between baseline (start of treatment) and days 28 and 56 (end of treatment)

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in CD4+ and CD8+ T Cell Count on Days 28 and 56.

Exploratory Outcome - Change from baseline in CD4+ and CD8+ T cell count

Time frame:
Change between baseline (start of treatment) and days 28 and 56 (end of treatment)

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in Transforming Growth Factor Beta 1 (TGF beta1) on Days 28 and 56

Exploratory Outcome - change in TGF-b1 from baseline to days 28 and 56 (end of treatment)

Time frame:
Change between baseline (start of treatment) and days 28 and 56 (end of treatment)

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in C-reactive Protein (CRP) on Days 28 and 56

Exploratory Outcome - Change in C-reactive Protein (CRP) from baseline to Days 28 and 56 (end of treatment)

Time frame:
Change between baseline (start of treatment) and days 28 and 56 (end of treatment)

Results for this outcome have not been posted.

Other pre-specifiedChange From Baseline in CCR5 Receptor Occupancy on Days 28 and 56.

Exploratory Outcome - Change in CCR5 receptor occupancy from baseline and days 28 and 56 (end of treatment)

Time frame:
Change between baseline (start of treatment) and days 28 and 56 (end of treatment)

Results for this outcome have not been posted.

Other pre-specifiedExploration of Biomarkers That May Predict and/or Act as Pharmacodynamic Indicators of Pharmacologic Activity of Leronlimab.

Exploratory Outcome - Exploration of biomarkers that may predict and/or act as pharmacodynamic indicators of pharmacologic activity of leronlimab.

Time frame:
91 Days

Results for this outcome have not been posted.

Other pre-specifiedIncidence of Treatment-related Adverse Events (TEAEs)

Safety Measurement - incidence of treatment emergent adverse events

Time frame:
Between baseline and day 91

Results for this outcome have not been posted.

Other pre-specifiedIncidence and Severity of Treatment-emergent Adverse Events (TEAEs)

Safety Measures - Incidence and severity of treatment-emergent adverse events

Time frame:
Between baseline and day 91

Results for this outcome have not been posted.

Other pre-specifiedIncidence of Serious Adverse Events (SAEs)

Safety Measures - incidence of severe adverse events

Time frame:
Between baseline and day 91

Results for this outcome have not been posted.

Other pre-specifiedIncidence of TEAEs and SAEs Leading to Discontinuation of Study Medication.

Safety Measures - incidence of TEAEs and SAEs leading to discontinuation of study medication

Time frame:
Between baseline and day 56

Results for this outcome have not been posted.

Other pre-specifiedChanges in Blood Chemistry, Hematology and Coagulation Parameter Results

Safety Measures - Changes in blood chemistry, hematology and coagulation parameter results

Time frame:
Between baseline and day 91

Results for this outcome have not been posted.

Other pre-specifiedChanges in Vital Signs Including Temperature, Pulse, Respiratory Rate, Systolic and Diastolic Blood Pressure

Safety Measures - Changes in vital signs including temperature, pulse, respiratory rate, systolic and diastolic blood pressure

Time frame:
Between baseline and day 91

Results for this outcome have not been posted.

Other pre-specifiedChanges in Physical Examination Results

Safety Measures - Changes in physical examination results

Time frame:
Between baseline and day 91

Results for this outcome have not been posted.

Other pre-specifiedChanges in Electrocardiogram (ECG) Results

Safety Measures - changes in electrocardiogram results

Time frame:
Change between baseline and day 91

Results for this outcome have not been posted.

Adverse events

Collected over Adverse event data was collected between start of treatment (baseline, day 0) and 28 days after end of treatment. First dose was administered on Day 0, last dose (dose 8) was administered on day 49, End of Treatment (EOT) was 7 days after last dose (day 56) and follow-up was for the 28 day period after the EOT visit.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
700mg Leronlimab0/28 (0%)0/28 (0%)22/28 (78.6%)
Placebo0/28 (0%)1/28 (3.6%)20/28 (71.4%)
Most frequent serious events
Most frequent serious events
Event700mg LeronlimabPlacebo
Seizures and seizure disordersNervous system disorders0/281/28
Most frequent other events
Showing 10 of 85
Most frequent other events
Event700mg LeronlimabPlacebo
Urinary tract infectionInfections and infestations2/284/28
HypokalaemiaMetabolism and nutrition disorders0/283/28
AnxietyPsychiatric disorders3/280/28
RashSkin and subcutaneous tissue disorders1/283/28
DiarrhoeaGastrointestinal disorders0/282/28
NauseaGastrointestinal disorders1/282/28
VomitingGastrointestinal disorders2/280/28
Chest PainGeneral disorders2/280/28
Injection site reactionGeneral disorders2/280/28
MalaiseGeneral disorders2/280/28

Baseline characteristics

The Modified Intent-to-Treat (mITT) population is defined as the set of subjects who have received at least one dose of study treatment (leronlimab or placebo). This population was used for the analysis of efficacy parameters or measurements. The Safety Population includes all subjects who received one dose of study treatment (leronlimab or placebo). This population was used for the analysis of safety parameters or measurements.

Age, Categorical
Age, Categorical(Participants)700mg LeronlimabPlaceboTotal
<=18 years000
Between 18 and 65 years262349
>=65 years257
Age, Continuous
Age, Continuous(years)700mg LeronlimabPlaceboTotal
Mean45.5 ± 12.851.6 ± 13.248.6 ± 13.24
Sex: Female, Male
Sex: Female, Male(Participants)700mg LeronlimabPlaceboTotal
Female181836
Male101020
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)700mg LeronlimabPlaceboTotal
Hispanic or Latino314
Not Hispanic or Latino252752
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)700mg LeronlimabPlaceboTotal
American Indian or Alaska Native011
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White282755
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)700mg LeronlimabPlaceboTotal
United States282856
Baseline COVID-19 Related Symptom Score
Baseline COVID-19 Related Symptom Score(units on a scale)700mg LeronlimabPlaceboTotal
Mean32.5 ± 9.9626.9 ± 10.1929.4 ± 10.64
08

Study locations

2 sites
  • Arthritis & Rheumatic Disease Specialties
    Aventura, Florida 33180, United States
  • Center for Advanced Research & Education (CARE)
    Gainesville, Georgia 30501, United States
09

References and documents

Publications

  • Gaylis NB, Ritter A, Kelly SA, Pourhassan NZ, Tiwary M, Sacha JB, Hansen SG, Recknor C, Yang OO. Reduced Cell Surface Levels of C-C Chemokine Receptor 5 and Immunosuppression in Long Coronavirus Disease 2019 Syndrome. Clin Infect Dis. 2022 Sep 30;75(7):1232-1234. doi: 10.1093/cid/ciac226. PubMed 35452519 ↗
  • Chang XL, Wu HL, Webb GM, Tiwary M, Hughes C, Reed JS, Hwang J, Waytashek C, Boyle C, Pessoa C, Sylwester AW, Morrow D, Belica K, Fischer M, Kelly S, Pourhassan N, Bochart RM, Smedley J, Recknor CP, Hansen SG, Sacha JB. CCR5 Receptor Occupancy Analysis Reveals Increased Peripheral Blood CCR5+CD4+ T Cells Following Treatment With the Anti-CCR5 Antibody Leronlimab. Front Immunol. 2021 Nov 19;12:794638. doi: 10.3389/fimmu.2021.794638. eCollection 2021. PubMed 34868084 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jun 2021, 3 months.

Results were first posted in Apr 2024, 2 years 10 months after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 3 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2020
First posted
Dec 22, 2020
StartActual
Mar 1, 2021
Primary completionActual
Jun 5, 2021
CompletionActual
Jul 8, 2021
Results first posted
Apr 11, 2024
Last update
Apr 11, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04678830
Lead sponsor
CytoDyn, Inc.
Collaborators
Amarex Clinical Research
Responsible party
Sponsor
First posted
Dec 22, 2020
Start date
Mar 1, 2021
Primary completion
Jun 5, 2021
Completion
Jul 8, 2021
Results posted
Apr 11, 2024
Last update
Apr 11, 2024

Study contacts

Norman Gaylis, MD
principal investigator · Arthritis and Rheumatic Disease Specialties Aventura Florida

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leronlimab

Start the discussion